Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219127 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL1781352 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL29688566 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL4802159 | 1.00 | MBOAT4 (0.62) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL3268576 | 0.81 | MBOAT4 (0.53) | MBOAT4CYP19A1CDK5CDK5R1NR1I3 | |
| SCHEMBL1788661 | 0.80 | MBOAT4 (0.46) | MBOAT4CYP19A1GRIN1GRIN2BSHBG | |
| SCHEMBL2186022 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG | |
| SCHEMBL1287860 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG | |
| SCHEMBL1287861 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG | |
| SCHEMBL9512557 | 0.79 | CYP19A1 (0.55) | CYP19A1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224214-A1 | HUMAN GHRELIN O-ACYLTRANSFERASE INHIBITORS | SYRACUSE UNIVERSITY (US) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190224214-A1 | HUMAN GHRELIN O-ACYLTRANSFERASE INHIBITORS | MBOAT4, LCAT, ACAT1 | MBOAT4 1/4885CYP19A1 66/4885CDK5 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.